Timing of plasma exchange and rituximab for the treatment of thrombotic thrombocytopenic purpura [1]

American Journal of Clinical Pathology

Volumn 126, Issue 6, 2006, Pages 965-

  Boctor, Fouad N ^a   Smith, John A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIBODY; CD20 ANTIBODY; CORTICOSTEROID; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; HUMAN; LETTER; PLASMA VOLUME; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HALF-LIFE; HUMANS; IMMUNOLOGIC FACTORS; METHYLPREDNISOLONE; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TIME FACTORS; VINCRISTINE;

EID: 33845428648     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Darabi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol. 2006;125:592-597.
2. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457-2466.
3. Klein HG. Therapeutic hemophoresis. In: Petz LD, Kleinman S, Swisher SN, et al, eds. Clinical Practice of Transfusion Medicine. 3rd ed. New York, NY: Churchill Livingstone; 1996:1011-1022.
4. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-397.